Pathology: Bronchitis Therapeutics

• Publication date: December 2011

What's inside this report? GlobalData, the market analysis specialist, has released its new report, “”. The report is an essential source of information and analysis on the global bronchitis therapeutics industry . The report identifies the major industry developments shaping and driving the global bronchitis therapeutics industry . The report also provides insights into the competitive landscape and the emerging players expec...

What's inside this report?

GlobalData, the market analysis specialist, has released its new report, “”. The report is an essential source of information and analysis on the global bronchitis therapeutics industry . The report identifies the major industry developments shaping and driving the global bronchitis therapeutics industry . The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing industry leaders. Most importantly, the report provides valuable insights into the new product development within the global bronchitis segment .

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

The global bronchitis industry was valued at USD 459m in 2009 and is projection to decline by 3.5% annually for the next seven years to reach USD 344m in 2017. The typical form of bronchitis is self-limited. The bronchitis industry is characterized by many generics and OTC. The NSAIDs (Non Steroidal Anti Inflammatory Drugs), cough suppressants and antipyretics are mere supportive therapies. Antibiotics are highly prescribed to treat atypical form of the disease. The decrease in the industry size is attributed to the patent expiration of the branded drugs and the up take of generic drugs

Research Scope

- The scope of the report includes:
- Annualized global Bronchitis therapeutics industry revenue data from 2001 to 2009, projection for eight years to 2017.
- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include Topoisomerase II and topoisomerase IV inhibitor, MSC therapy, Oral PDE-IV Inhibitor, and mucomodulator and antioxidant agent.
- Analysis of the current and future industry competition in the global bronchitis therapeutic industry . The key future industry players covered are Osiris Therapeutics, GlaxoSmithKline, Pacific Beach Biosciences, Inc., Pfizer and Edmond Pharma Srl.
- Insightful review of the key market drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, a industry characterization, the unmet needs and the implications for the bronchitis industry .

Reasons to buy

- The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of new product development and technologies and by identifying the industry players with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global bronchitis therapeutics industry .
- Drive revenues by understanding the major industry developments, innovative products and technologies, industry sectors and industry players likely to affect the global bronchitis therapeutics industry in the future.
- Formulate effective sales and industry ing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present the best opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the global bronchitis therapeutics industry landscape? Identify, understand and decide.

Therapy Industry in the United Kingdom

Table of Contents


I Table of contents 2
I. 1 List of Data tables 3
I. 2 List of Charts 3

II Bronchitis Therapeutics: Introduction 4
II. 1 Overview 4
II. 1.1 Risk Factors 5
II. 1.2 Treatment Options 5
II. 1.3 Scope of the Report 5
II. 2 GlobalData Pipeline Report Guidance 6

III Bronchitis Thrapeutics: March ket Characterization 7
III. 1 Bronchitis March ket Size 7
III. 2 Bronchitis March ket Forecasted data and CAGR 8
III. 3 Drivers and Barriers for the Bronchitis March ket 10
III. 3.1 Drivers for the Bronchitis March ket 10
III. 3.2 Barriers for the Bronchitis March ket 10
III. 4 Opportunity and Unmet Need 11
III. 5 Key Takeaway 12
4 World Bronchitis March ket: Competitive Assessment 13
IV. 1 Overview 13
IV. 2 Strategic Competitor Assessment 13
IV. 3 Product Profile for the Major March keted Products in the Bronchitis March ket 14
IV. 3.1 Antivirals 14
IV. 3.2 Antibiotics 15
IV. 3.3 Bronchodilators and beta2 agonists 16
IV. 3.4 Analgesics and NSAIDs 18
IV. 4 Key Takeaway 19

V Bronchitis Therapeutics: Pipeline Assessment 20
V. 1 Overview 20
V. 2 Strategic Pipeline Assessment 20
V. 3 Product Profiles of the Most Promising Products in the Bronchitis March ket 22
V. 3.1 Prochymal 22
V. 4 Bronchitis March ket – Clinical Pipeline by Mechanism of Action 23
V. 4.1 Bronchitis Disease – Phase III Clinical Pipeline 24
V. 4.2 Bronchitis Disease – Phase II Clinical Pipeline 24
V. 5 Key Takeaway 24
6 World Bronchitis March ket: Implications for Future March ket Competition 25

VII Bronchitis Therapeutics: Future Players 26
VII. 1 Introduction 26
VII. 2 Pfizer Inc. 27
VII. 2.1 Company Profile 27
VII. 2.2 Business Overview 27
VII. 2.3 Respiratory Disease Pipeline Product Portfolio 29
VII. 3 Osiris Therapeutics, Inc. 29
VII. 3.1 Company Profile 29
VII. 3.2 Business Overview 29
VII. 3.3 Respiratory Disease Pipeline Product Portfolio 30
VII. 4 GlaxoSmithKline 30
VII. 4.1 Company Profile 30
VII. 4.2 Business Overview 31
VII. 4.3 Respiratory Disease Pipeline Product Portfolio 32

VIII Bronchitis Therapeutics: Appendix 33
VIII. 1 Definitions 33
VIII. 2 Acronyms 33
VIII. 3 Research Methodology 33
VIII. 3.1 Coverage 34
VIII. 3.2 Secondary Research 34
VIII. 3.3 Forecasted data ing 34
VIII. 3.4 Primary Research 37
VIII. 3.5 Expert Panel Validation 37
VIII. 4 Contact Us 37
VIII. 5 Disclaimer 37
VIII. 6 Sources 38

List of Tables

I. 1 List of Data tables
Data table 1: Bronchitis Therapeutics, Global, Sales (USD Million), 2001–2009 8
Data table 2: Bronchitis Therapeutics, Global, March ket Forecasted data (USD Million), 2009–2017 9
Data table 3: Major March keted Products Comparison for Bronchitis, 2010 19
Data table 4: Bronchitis Therapeutics – Phase III Clinical Pipeline, 2010 24
Data table 5: Bronchitis Therapeutics – Phase II Clinical Pipeline, 2010 24
Data table 6: Pfizer Inc. – Respiratory Disease Pipeline, 2010 29
Data table 7: Osiris Therapeutics Inc. – Respiratory Disease Pipeline, 2010 30
Data table 8: GlaxoSmithKline plc – Respiratory Disease Pipeline Products, 2010 32

List of Figures

I. 2 List of Charts
Chart 1: Bronchitis Therapeutics, Global, Sales (USD Million), 2001–2009 8
Chart 2: Bronchitis Therapeutics, Global, March ket Forecasted data (USD Million), 2009–2017 9
Chart 3: Opportunity and Unmet Need in the Bronchitis Therapeutics March ket 12
Chart 4: Strategic Competitor Assessment, 2010 13
Chart 5: Technology Trends Analytics Framework of the Bronchitis Therapeutics Pipeline, 2010 20
Chart 6: Technology Trends Analytics Framework of the Bronchitis Therapeutics Pipeline – Description, 2010 21
Chart 7: Bronchitis March ket – Clinical Pipeline by Mechanism of Action, 2010 23
Chart 8: Bronchitis Therapeutics March ket – Clinical Pipeline by Phase of Development, 2010 23
Chart 9: Implications for Future March ket Competition in the Bronchitis Therapeutics March ket, 2010 25
Chart 10: Bronchitis Therapeutics March ket – Pipeline by Firms, 2010 26
Chart 11: GlobalData March ket Forecasted data ing Model 36

Companies Mentioned

Pfizer Inc
Osiris Therapeutics, Inc.
GlaxoSmithKline